Price
No data yet.
Social Signal Score
Analyst Ratings
15 analystsRevenue
$-1.47M-104.90%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Thane Wettig
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 34
- Beta
- 1.06
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -25.84
Financials
Revenue
$-1.47M-104.9%Net Income
$11.97MEBITDA
$-49.49MFree Cash Flow
$-3.99MEPS (diluted)
$2.96Shares Outstanding (diluted)
4.05M+61.0%Operating Expenses
$16.09MCash & Debt
$91.32MReturn of Capital
$5.0KRevenue by Segment (annual)
$5.85MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $6.44M | $183.45M | $45.37 |
| 2024 | $29.62M | $-47.58M | $-0.48 |
| 2023 | $46.80M | $-284.23M | $-2.92 |
| 2022 | $140.73M | $-293.65M | $-3.15 |
| 2021 | $235.31M | $-290.02M | $-3.15 |
| 2020 | $176.32M | $-189.29M | $-2.11 |
| 2019 | $256.58M | $-76.97M | $-0.89 |
| 2018 | $212.96M | $-86.42M | $-1.03 |
| 2017 | $125.67M | $-126.20M | $-1.73 |
| 2016 | $179.58M | $-61.68M | $-0.98 |
| 2015 | $180.83M | $-85.78M | $-1.42 |
| 2014 | $137.60M | $-59.50M | $-1.04 |
| 2013 | $102.17M | $-14.94M | $-0.32 |
| 2012 | $65.93M | $-32.57M | $-2.47 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $66.67
- Implied price
- $1,200
- Return from $6.11
- 187.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $596.65 — today's price is already 99.0% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | 140.6% | 151.5% | 160.9% | 169.0% | 176.3% |
| 3.0% | 152.8% | 164.4% | 174.2% | 182.8% | 190.4% |
| 8.0% | 165.1% | 177.2% | 187.5% | 196.5% | 204.5% |
| 13.0% | 177.4% | 190.0% | 200.8% | 210.2% | 218.6% |
| 18.0% | 189.7% | 202.9% | 214.1% | 224.0% | 232.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·5d ago·Neutral
Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors SAN FRANCISCO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the appointment of Andrew E. Singer, MBA to its Board of Directors as an independent director and member of the Audit Committee effective October 1, 2026. The Company also announced that Maykin Ho, Ph.D. has stepped down from the Board of Directors effective September 30, 2026 after nearly eight years of service.
View source ↗ - Newsglobenewswire.com·35d ago·Negative
Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the signing of an amendment and restatement of its existing royalty financing agreement with NQ Project Phoebus, L.P., materially reducing its payment obligations under the agreement in exchange for an accelerated upfront payment.
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·53d ago·Negative
Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates Kyntra Bio (KYNB) came out with a quarterly loss of $4.68 per share versus the Zacks Consensus Estimate of a loss of $3.18. This compares to a loss of $3.38 per share a year ago.
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-3.66 per share
Typical surprise -11.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$2.96 vs $-3.18beat
- Mon, May 11$-3.74 vs $-3.36miss
- Mon, Mar 16$-3.51 vs $-3.89beat
- Mon, Nov 10$-1.61 vs $-4.01beat
- Mon, Aug 11$-3.38 vs $-2.25miss
- Mon, May 12$0.05 vs $0.75miss
Estimates and results for KYNB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by KYNB officers and directors.
- Bought
- $470k
- Sold
- —
10 trades
0 trades
- Wettig Thanebought
- Wettig Thanebought
- Wettig Thanebought
- Wettig Thanebought
- Schoeneck James Abought
- Wettig Thanebought
- Schoeneck James Abought
- Schoeneck James Abought
90 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in KYNB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.